investigation. The remaining 64 (75%) were subsequently admitted to 29 different locations (8 medical specialities, surgical, vascular and orthopaedic wards). Of these, 55 (86%) were seen by the lung CNS within one working day and an appropriate management plan initiated. This was aided by our live CT database, where 50 suspicious scans were coded the same day enabling early review by the lung clinician and CNS, often before formal referral from the responsible clinical team was made.
Background The development of drugs that target lung adenocarcinoma caused by epidermal growth factor tyrosine kinase (EGFR-TK) and anaplastic lymphoma kinase (ALK) mutations has focused the need to obtain sufficient tissue at biopsy to allow the detection of such molecular markers and so improve treatment options for selected patients. To investigate this further, we looked at the diagnostic yield from various biopsy techniques in our large lung cancer unit (400 cases per year, overall histological yield 77.5%). Methods We collected data from all patients with an ultimate histological diagnosis of adenocarcinoma for the years 2014 to 2016, looking at the diagnostic method, whether tissue was analysed for molecular mutations, and whether repeat procedures were necessary for EGFR-TK and ALK testing. Results 224 patients were identified: 42 by EBUS-TBNA, 66 by CT-guided biopsy, 44 at bronchoscopy, 66 at surgical resection, 6 from pleural fluid, and 1 by lymph node FNA. For molecular testing see Table. In addition to those patients where sampling was insufficient to make the diagnosis, a further 30 had inadequate cell numbers for mutation analysis and the reporting pathologist recommended repeat procedures. Of the 10 patients who underwent this, only 2 were retested for molecular markers, and the Results were unchanged. Conclusion This study shows that all our pre-resection positive diagnostic samples for lung cancer do not always provide sufficient tissue for molecular analysis. Although insufficiency rates were similar between CT, EBUS and bronchoscopy, one third of CT-guided specimens had few cells for the definite exclusion of mutations. With the advent of new therapies for lung cancer, we need to optimise our diagnostic sampling techniques when testing for molecular mutations. COPD remains a leading cause of healthcare use despite the availability of effective inhaled therapies. We examined adherence to maintenance therapy by assessing the key components of good inhaler use: habit of use and inhaler technique. The relationship between adherence patterns, specific patient characteristics and clinical outcomes at one year was examined. We recruited 226 hospitalised patients with a diagnosis of COPD to this prospective observational study. Inhaler adherence was remotely monitored for 90 days after hospital discharge using an INCA TM audio recording device. Cluster analysis grouped patients by their adherence behaviour based on the mean rate of attempted use and critical technique errors. The clinical and psychosocial characteristics of each cluster were examined. The rate of all-cause mortality and healthcare use at 12 months was recorded. Survival analysis was used to evaluate the time to first event across adherence groups. Adherence data was available for 195 patients. We identified four patterns of Adherence behaviour: (1) Regular habit of use and good technique (28%); (2) Regular habit of use and poor technique (21%); (3) Poor habit of use and good technique (33%); (4) Poor habit of use and poor technique (19%). The overall event rate was lowest in Cluster 1, 5.46/person/year. Cluster 2 had the lowest annual rate of hospital presentation, but accounted for the majority of community prescriptions for antibiotics and steroids, mean 4.6/person/ Poster sessions
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